255 related articles for article (PubMed ID: 32152926)
1. Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.
Soukhtanloo M; Mohtashami E; Maghrouni A; Mollazadeh H; Mousavi SH; Roshan MK; Tabatabaeizadeh SA; Hosseini A; Vahedi MM; Jalili-Nik M; Afshari AR
Pharmacol Rep; 2020 Apr; 72(2):285-295. PubMed ID: 32152926
[TBL] [Abstract][Full Text] [Related]
2. Protective Role of Natural Products in Glioblastoma Multiforme: A Focus on Nitric Oxide Pathway.
Afshari AR; Mollazadeh H; Mohtashami E; Soltani A; Soukhtanloo M; Hosseini A; Jalili-Nik M; Vahedi MM; Roshan MK; Sahebkar A
Curr Med Chem; 2021; 28(2):377-400. PubMed ID: 32000638
[TBL] [Abstract][Full Text] [Related]
3. NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.
Gray GK; McFarland BC; Nozell SE; Benveniste EN
Expert Rev Neurother; 2014 Nov; 14(11):1293-306. PubMed ID: 25262780
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Calcium Signaling in Glioblastoma Multiforme: A Therapeutic Promise for Natural Products.
Afshari AR; Mollazadeh H; Soukhtanloo M; Hosseini A; Mohtashami E; Jalili-Nik M; Modaresi SMS; Soltani A; Sahebkar A
Mini Rev Med Chem; 2020; 20(18):1879-1899. PubMed ID: 32767939
[TBL] [Abstract][Full Text] [Related]
5. NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.
Avci NG; Ebrahimzadeh-Pustchi S; Akay YM; Esquenazi Y; Tandon N; Zhu JJ; Akay M
Sci Rep; 2020 Aug; 10(1):13352. PubMed ID: 32770097
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
7. The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma.
Shi P; Xu J; Cui H
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373484
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.
Cahill KE; Morshed RA; Yamini B
Neuro Oncol; 2016 Mar; 18(3):329-39. PubMed ID: 26534766
[TBL] [Abstract][Full Text] [Related]
9. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
11. Small GTPase RHOE/RND3, a new critical regulator of NF-κB signalling in glioblastoma multiforme?
Sun Q; Dong H; Li Y; Yuan F; Xu Y; Mao S; Xiong X; Chen Q; Liu B
Cell Prolif; 2019 Sep; 52(5):e12665. PubMed ID: 31332862
[TBL] [Abstract][Full Text] [Related]
12. Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner.
Lindemann C; Marschall V; Weigert A; Klingebiel T; Fulda S
Neoplasia; 2015 Jun; 17(6):481-9. PubMed ID: 26152356
[TBL] [Abstract][Full Text] [Related]
13. Targeting Key Signaling Pathways in Glioblastoma Stem Cells for the Development of Efficient Chemo- and Immunotherapy.
Helweg LP; Storm J; Witte KE; Schulten W; Wrachtrup L; Janotte T; Kitke A; Greiner JFW; Knabbe C; Kaltschmidt B; Simon M; Kaltschmidt C
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361720
[TBL] [Abstract][Full Text] [Related]
14. IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.
Rinkenbaugh AL; Cogswell PC; Calamini B; Dunn DE; Persson AI; Weiss WA; Lo DC; Baldwin AS
Oncotarget; 2016 Oct; 7(43):69173-69187. PubMed ID: 27732951
[TBL] [Abstract][Full Text] [Related]
15. Natural Small Molecules Targeting NF-κB Signaling in Glioblastoma.
Uddin MS; Kabir MT; Mamun AA; Sarwar MS; Nasrin F; Emran TB; Alanazi IS; Rauf A; Albadrani GM; Sayed AA; Mousa SA; Abdel-Daim MM
Front Pharmacol; 2021; 12():703761. PubMed ID: 34512336
[TBL] [Abstract][Full Text] [Related]
16. Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB.
Anderson KN; Bejcek BE
J Pharmacol Sci; 2008 Feb; 106(2):318-20. PubMed ID: 18277052
[TBL] [Abstract][Full Text] [Related]
17. Tetrandrine inhibits human brain glioblastoma multiforme GBM 8401 cancer cell migration and invasion in vitro.
Jiang YW; Cheng HY; Kuo CL; Way TD; Lien JC; Chueh FS; Lin YL; Chung JG
Environ Toxicol; 2019 Apr; 34(4):364-374. PubMed ID: 30549224
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
19. NFκB inhibitors induce cell death in glioblastomas.
Zanotto-Filho A; Braganhol E; Schröder R; de Souza LH; Dalmolin RJ; Pasquali MA; Gelain DP; Battastini AM; Moreira JC
Biochem Pharmacol; 2011 Feb; 81(3):412-24. PubMed ID: 21040711
[TBL] [Abstract][Full Text] [Related]
20. Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction.
Khan M; Yi F; Rasul A; Li T; Wang N; Gao H; Gao R; Ma T
IUBMB Life; 2012 Sep; 64(9):783-94. PubMed ID: 22837216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
